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Abstract
The occurrence of metabolic syndrome is a risk factor for developing cardiovascular disease. Moreover, the size of low-
-density lipoprotein (LDL) particles, and liver dysfunction identified as non-alcoholic fatty liver disease (NAFLD), both 
represent important biomarkers for the development of cardiometabolic risk in patients with metabolic syndrome. Pa-
tients being treated with bergamot polyphenolic fraction show significant reductions in fasting plasma glucose, serum 
LDL cholesterol, and triglycerides along with an increase of their high-density lipoprotein cholesterol level. This effect is 
accompanied in the ultrasonography examination by significantly reduced NAFLD.
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Definition of metabolic syndrome
Metabolic syndrome is characterised by the coexistence 
of metabolic risk factors for atherosclerosis and its com-
plications. The modified definition by the National Cho-
lesterol Education Programme Adult Treatment Panel III 
(NCEP-ATP III) includes:
 — obesity defined as waist circumference ≥ 88 cm among 
women and ≥ 102 cm among men;
 — fasting glucose ≥ 100 mg/dL or glucose lowering 
treatment;
 — systolic blood pressure ≥ 130 mm Hg, diastolic blood 
pressure ≥ 85 mm Hg or antihypertensive treatment;
 — triglycerides level (TG) ≥ 150 mg/dL (≥ 1.7 mmol/L) or 
lipid lowering therapy;
 — high-density lipoprotein cholesterol level (HDL-C, 
< 40 mg/dL (< 1.0 mmol/L) among men, < 50 mg/dL 
(< 1.3 mmol/L) among women or lipid-modifying therapy.
According to this definition, it is necessary to identify at 
least three of the abnormalities described above in order 
to make a diagnosis of metabolic syndrome [1].
Prevalence of metabolic syndrome  
and its complications
The prevalence of metabolic syndrome increases with age, 
and is around 40% in people over 60 years of age. In the 
general European population, the occurrence of metabolic 
syndrome is estimated at 38% in men and 36% in women, 
with its frequency increased significantly in the diabetic 
population. Metabolic syndrome, even without co-existing 
type 2 diabetes, significantly increases the risk of develo-
ping ischaemic heart disease. The incidence of diabetes in 
people with central obesity, which is the main component 
of metabolic syndrome, increases 3–4 times compared to 
people with normal body weight. Hypertension and lipid 
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disorders are also more common in overweight and obese 
people. In addition, people with metabolic syndrome are 
more likely to have decreased levels of adiponectin A1, 
insulin resistance, thrombophilia, inflammation, endothelial 
dysfunction, hepatic steatosis, elevated uric acid, leptin, 
fibrinogen, low-density lipoprotein cholesterol (LDL-C) and 
increased alanine transaminase.
Numerous observations have indicated that inflam-
mation plays a key role in the pathogenesis of virtually all 
components of metabolic syndrome, so this may be the 
most important mechanism underlying this disease, second 
only to an abnormal lifestyle [1–4].
Therapeutic treatment  
in metabolic syndrome
Treatment and prevention of metabolic syndrome involve 
primarily a change in lifestyle. The effectiveness of such 
a change, which has a positive effect on all the elements 
of metabolic syndrome, is observed even with fairly small 
reductions of body weight and BMI. The beneficial role of 
diet has been confirmed in observational studies. Minimally 
processed fruits, vegetables, coarse bread, nuts and seeds, 
olive oil as the main source of fat in the diet, elements of the 
Mediterranean diet, and limited intake of dairy products, 
eggs and red meat, have all been seen to reduce mortality 
and the percentage of cardiac events, favourably affecting 
the various components of metabolic syndrome [4]. Due 
to the key role of inflammation and oxidative stress in the 
pathogenesis of endothelial dysfunction as the first stage 
of the atherosclerotic process, the basis for preventing the 
development of atherosclerosis in metabolic syndrome 
should be drugs that simultaneously inhibit both processes. 
Pharmacological treatment of diagnosed hypertension, 
diabetes mellitus and hypercholesterolemia in people 
with metabolic syndrome does not differ from the general 
principles of treatment of these disease entities in people 
without metabolic syndrome, but a strong focus upon the 
benefits and the need for lifestyle modification are always 
required. From the point of view of cardiovascular risk, 
moderate correction of several risk factors (if any) is more 
beneficial than focusing on just one while leaving the other 
factors without intervention. Although in the diagnosis of 
metabolic syndrome, increased LDL-C concentration does 
not fall within the diagnostic criteria, it should nonetheless 
be remembered that hypercholesterolemia is an extremely 
common phenomenon in the Polish population, further 
exacerbating the risk of cardiovascular complications [2, 4].
Natural substances in the prevention  
and therapy of cardiovascular diseases
In recent years, the possibility of using biologically active 
substances of plant origin in the prevention and treatment 
of ‘civilization diseases’ has received growing interest. 
Biologically active compounds of plant origin, with efficacy 
proven and confirmed in clinical trials, are perceived not 
only as cheaper but even more importantly as healthier 
alternatives or supplementations of traditional synthetic 
pharmaceuticals. The European guidelines for the treat-
ment of lipid disorders mention, among others, the need 
to increase fibre intake, for functional foods enriched with 
sterols, and for the use of cholesterol-lowering supplements 
(including red fermented rice).
Numerous clinical and epidemiological studies have 
proved that diet being the source of polyphenolic com-
pounds contributes to reducing the risk of occurrence of, 
among others, cardiovascular diseases, obesity, type 2 dia-
betes, and cancer. Substances with antioxidant properties 
are particularly valuable ingredients of plant materials. The 
main vegetable antioxidants include polyphenolic compo-
unds, which are the most widespread group of antioxidant 
compounds in the plant world. Polyphenolic compounds 
accumulate in the above-ground parts of plants, i.e. the 
stems, leaves and flowers and above all in the fruits. They 
are also responsible for their colour, which is why fruits with 
intense pigmentation are characterised by a high content of 
these compounds. Vegetables and spices, as well as drinks 
such as coffee, cocoa, green tea, black tea, and red wine, 
are also rich sources of polyphenols [5, 6].
Composition of bergamot polyphenols
Bergamot orange (Citrus bergamia Risso & Poiteau), also 
known as bergamot, is a species of citrus plant from the 
Rutaceae family. It probably originated in India, although 
today it is almost exclusively cultivated in the region of 
Calabria in southern Italy. The bergamot fruit is bitter and 
tart and not suitable for direct consumption. The main raw 
material for the production of bergamot oil is thick and 
wrinkled orange peel containing large amounts of essential 
oil. Bergamot juice is characterised by a unique flavonoid 
profile and is particularly rich in flavanones and flavones. 
The composition of bergamot polyphenols has been evalu-
ated in clinical trials in which, among others, patients with 
metabolic syndrome were included.
For the randomised, double-blind, placebo-controlled 
trial performed by Mollace et al. [7], 237 patients with 
hypercholesterolemia were qualified, and among this 
group were 59 patients with metabolic syndrome (mixed 
hyperlipidemia and glycaemia > 110 mg/dL). This group 
was divided into three subgroups, in which patients recei-
ved BPF 500 mg/day, 1,000 mg/day, or a placebo, while 
maintaining a diet of 1,600 kcal/day.
Thirty-day BPF therapy (500 mg or 1,000 mg) resulted in 
a significant reduction in total cholesterol (TC) and LDL-C and 
a significant increase in HDL-C (Table 1) [7]. There were no 
significant changes in lipid parameters in the placebo group.
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Additionally, the function of the vascular endothelium 
was monitored by brachial artery ultrasound imaging, as-
sessing the increase in its diameter during reactive hypere-
mia. Thirty-day BPF therapy (500 mg or 1,000 mg) resulted 
in a significant reduction in total and LDL-C and a significant 
increase in HDL-C (Table 1) [7]. There were no significant 
changes in lipid parameters in the placebo group.
A significant reduction was also observed in triglyce-
rides (TG) (Table 2). After high-dose BPF treatment, mean 
baseline values were of TC 278 mg/dL, of LDL-C 188 mg/dL 
and of TG 267 mg/dL. These were reduced to 199 mg/dL, 
126 mg/dL and 158 mg/dL respectively. LDL-C reduction 
was accompanied by a dose-dependent increase in HDL-C 
in all patients.
In 10% of people with the best response to treatment, 
the increase in HDL-C was extremely high: 64.6%. In addi-
tion, a significant (p < 0.0001) reduction in blood glucose 
was obtained (mean reduction of –18.9% in the BPF group 
at a dose of 500 mg and –22.4% in the BPF group at a dose 
of 1,000 mg). There were no significant changes in the 
glucose concentration in the placebo group (Table 2) [7].
In addition, the BPF 500 mg and 1,000 mg groups 
showed improvements in reactive hyperemia within the 
brachial artery, which would indicate a beneficial effect of 
BPF on the vascular endothelium in patients with lipid and 
carbohydrate disorders, which are important biomarkers 
of cardiometabolic risk. According to the authors of the 
study, oral BPF containing dietary supplements have hypo-
lipemic potency comparable to low doses of strong statins. 
In addition, the reduction of blood glucose by 15–25% 
suggests the possibility of a phytotherapeutic approach 
to the control of pre-diabetic states in patients with meta-
bolic syndrome. The supply of natural antioxidants, such 
as bergamot-derived polyphenols, has a positive effect on 
the modulation of cardiometabolic risk biomarkers and 
has additional vasoprotective potential in patients with 
metabolic syndrome.
Gliozzi et al. [8] conducted a study evaluating the in-
fluence of BPF on the lipoprotein subfraction profile (small 
dense LDL) and non-alcoholic fatty liver disease (NAFLD) 
in patients with metabolic syndrome. 107 people with me-
tabolic syndrome and NAFLD were qualified for the study, 
and were divided into two groups: a group receiving BPF at 
a dose of 650 mg BD and a group receiving a placebo for 
120 days. A significant reduction in TC, LDL-C, TG, glucose, 
transaminase, gamma-glutamyl transaminase levels, ‘ste-
ato-test’, morphological exponents of fatty liver on imaging 
and inflammatory biomarkers: high-sensitivity C-reactive 
protein (hs-CRP) and tumour necrosis factor α (TNF-α) was 
observed in the BPF-treated group (Table 3) [8].
In addition, significant changes were found in the mean 
size of very-low-density lipoproteins (VLDLs, LDL and HDL 
(p < 0.05). In particular, BPF reduced the concentration of 
intermediate-density lipoproteins (IDL) by 51%, increased 
the concentration of large LDL by 38%, and decreased the 
concentration of small LDL by 35%. Moreover, 120-day BPF 
therapy resulted in a 20 per cent increase in the concen-
tration of anti-atherogenic HDL particles, mainly due to the 
increase in HDL concentration (Table 4) [8].
In addition, the hepatorenal index decreased from 2.8 ± 
± 0.4 to 1.5 ± 0.5 (p < 0.05), which proved that BPF admi-
nistration to patients with mild to severe NAFLD associated 
with metabolic syndrome can lead to the reduction of stea-
tosis. During the study, no adverse effects associated with 
BPF intake were reported, which again confirmed the sig-
nificant safety profile of the bergamot extract. In summary, 
the authors found that bergamot polyphenols administered 
to patients with metabolic syndrome and NAFLD led to 
Table 1. Percentage changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol 
(HDL-C) in patients with metabolic syndrome undergoing 30-day treatment with a composition of bergamot polyphenolic fraction (source [7])
Patient group N = 59 Daily intake of BPF [mg] Average change [%]
TC LDL-C HDL-C
Metabolic syndrome 500 –24.7 ± 2.6 –26.8 ± 3.6 16.5 ± 1.6
1,000 –28.1 ± 2.6 –33.2 ± 3.0 29.6 ± 1.8
Placebo 0.5 ± 0.5 –0.9 ± 1.4 2.9 ± 2.0
Table 2. Percentage changes in triglyceride concentrations (TG, triglycerides) and glucose in patients undergoing 30-day treatment with 
a composition of bergamot polyphenolic fraction (source [7])
Patient group N = 59 Daily intake of BPF 
[mg]
Average change [%]
TG Glucose
Metabolic syndrome 500 –32.7 ± 2.5 –18.9 ± 1.2
1,000 –41.0 ± 2.6 –22.4 ± 1.0
Placebo 0.0 ± 0.6 –0.5 ± 0.7
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improved lipid profile and glycaemic status and a significant 
reduction in fatty liver disease. This effect, together with 
a decrease in the concentration of proatherogenic small 
dense LDL, and an increase in the concentration of anti-
-cancer HDL particles, sheds new light on the potential 
use of bergamot extract in reducing cardiovascular risk in 
patients with metabolic syndrome [8].
Another aspect of the beneficial effects of bergamot 
polyphenols on vascular endothelium is also noteworthy. 
Mollace et al. [9] showed that in patients with type 2 dia-
betes with erectile dysfunction, sexual function improved 
in the group treated with BPF at a dose of 650 mg BD after 
a 120-day treatment. This phenomenon was not observed 
in the placebo group.
Mechanism of bergamot polyphenols  
beneficial effects
The probable mechanism of hypoglycaemic and hypolipe-
mic flavonoids appears to be the activation of AMP-activa-
ted protein kinase (AMPK), which acts as an integrator of 
regulatory signals that monitor the systemic and cellular 
Table 3. Effect of 120-day treatment with a composition of 
polyphenols from bergamot (BPF, bergamot polyphenolic fra-
ction) at a dose of 650 mg bis die (BD) on blood biochemical pa-
rameters, inflammatory biomarkers and ultrasound parameters 
in patients with metabolic syndrome and non-alcoholic fatty liver 
disease (source [8])
Biomarkers Baseline BPF
Patients receiving BPF 
650 mg BD for 120 days
107
Age (years) 56 ± 12
Gender (M/F) 64/43
BMI [kg/m2] 29.4 ± 2.01 28.2 ± 1.53
Glucose [mg/dL] 118 ± 1.4 98 ± 0.8*
TC [mg/dL] 245 ± 8.3 182 ± 7.1*
LDL-C [mg/dL] 162 ± 4.3 101 ± 1.8*
HDL-C [mg/dL] 38 ± 3.8 49 ± 4*
TG [mg/dL] 232 ± 5.1 160 ± 4.8*
Steato-test 0.74 ± 0.12 0.44 ± 0.09*
ALT [U/L] 54 ± 5.4 36 ± 5.3*
AST [U/L] 52 ± 6.4 41 ± 5.2*
GGTP [IU/L] 38 ± 5.2 29.33 ± 1.1*
hs-CRP [mg/L] 1.2 + 0.8 0.94 + 0.6*
TNF-α [pg/mL] 14.4 ± 1.9 10.7 ± 1.7*
Hepatorenal index 2.8 ± 0.4 1.5 ± 0.5*
*p < 0.05 (compared to baseline); M — men; F — women; BMI — body mass index; TC — total  
cholesterol; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein choleste-
rol; TG — triglycerides; ALT — alanine aminotransferase; AST — aspartate aminotransferase;  
GGTP — gamma-glutamyl transpeptidase; hs-CRP — high-sensitivity C-reactive protein;  
TNF-α — tumour necrosis factor α
Table 4. Effect of 120-day treatment with a composition of berga-
mot polyphenolic fraction (BPF) at a dose of 650 mg bis die (BD) 
on the size of lipoproteins and the concentration of their individu-
al fractions in the blood in patients with metabolic syndrome and 
non-alcoholic fatty liver disease (source [8])
Lipoprotein — size [nm] Baseline BPF
VLDL 55.3 ± 6.4 44.5 ± 5.2*
LDL 22.6 ± 1.7 18.0 ± 0.8*
HDL 7.5 ± 0.8 9.6 ± 0.9*
Lipoprotein fractions — concentration [nmol/L]
Total VLDL 83 ± 14 54 ± 12*
Large VLDL 4.2 ± 2 1.8 ± 1.3*
Medium VLDL 31 ± 9 14 ± 8*
Small VLDL 43 ± 9 38 ± 10
Total LDL 1,477 ± 75 1,293 ± 101*
IDL 77 ± 16 38 ± 10*
Large LDL 424 ± 87 653 ± 95*
Medium LDL 986 ± 105 612 ± 98*
Total HDL 30 ± 2 36 ± 3*
Large HDL 5 ± 3 15 ± 4*
Medium HDL 7 ± 4 7 ± 3
Small HDL 18 ± 5 14 ± 4*
*p < 0.05 (compared to baseline); VLDL — very-low-density lipoproteins; LDL — low-density lipopro-
teins; HDL — high-density lipoproteins; IDL — intermediate density lipoproteins
energy state of the body. As a result of the action of kinase, 
the synthesis of glucose, fats, proteins and cell growth is 
inhibited, while the uptake and oxidation of fatty acids, 
glucose uptake and glycolysis are stimulated. In addition, 
chronic activation of AMPK mimics the effect of intense 
physical exercise through the induction of muscle hexoki-
nase expression and glucose transporters type 4 (GLUT-4). 
The activation of AMPK is, therefore, a molecular activity 
of many natural polyphenols and may be responsible for 
their numerous beneficial therapeutic properties, especially 
in the context of metabolic disorders like obesity, diabe-
tes, hyperlipidemia and non-alcoholic fatty liver disease 
(NAFLD). Some flavonoids may induce lipolysis in adipose 
tissue, presumably by inhibiting phosphodiesterase (PDE) 
and reducing the distribution of cyclic adenosine mono-
phosphate (cAMP). This may explain the beneficial effects 
on obesity of some dietary supplements rich in citrus 
flavonoids. CAMP signalling pathways also modulate gluco-
neogenesis, glycogenolysis and insulin secretion [10–13]. 
There are also reports on BPH pleiotropic activities such as 
the reduction of chronic pain transmission by affecting the 
reactive oxygen species (ROS) and nitrogen (RNS), which 
are responsible for pain progression.
The composition of bergamot polyphenols also effecti-
vely limits the effects of ultraviolet B (UVB) on keratinocytes 
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Table 5. Intervention strategies as a function of total cardiovascular (CV) risk and low-density lipoprotein cholesterol (LDL-C) level  
(source [4])
Total CV risk 
(SCORE) 
[%]
LDL-C levels
< 70 mg/dL 70 to < 100 mg/dL 100 to < 155 mg/dL 155 to < 190 mg/dL ≥ 190 mg/dL
< 1.8 mmol/L 1.8 to < 2.5 mmol/L 2.5 to < 4.0 mmol/L 4.0 to < 4.9 mmol/L ≥ 4.9 mmol/L
< 1 No lipid interven-
tion
No lipid intervention No lipid intervention No lipid intervention Lifestyle intervention, 
consider drug if un-
controlled
≥ 1 and < 5 No lipid interven-
tion
No lipid intervention Lifestyle interven-
tion, consider drug if 
uncontrolled
Lifestyle interven-
tion, consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if un-
controlled
≥ 5 and < 10 No lipid interven-
tion
Lifestyle interven-
tion, consider drug if 
uncontrolled
Lifestyle intervention 
and concomitant 
drug intervention
Lifestyle intervention 
and concomitant 
drug intervention
Lifestyle intervention 
and concomitant 
drug intervention
≥ 10 Lifestyle interven-
tion, consider 
drug if uncon-
trolled
Lifestyle intervention 
and concomitant 
drug intervention
Lifestyle intervention 
and concomitant 
drug intervention
Lifestyle intervention 
and concomitant 
drug intervention
Lifestyle intervention 
and concomitant 
drug intervention
SCORE — Systematic COronary Risk Evaluation
Figure 1. Possibilities of using a composition of bergamot polyphenolic fraction (BPF) depending on the clinical situation based on the total 
risk of developing cardiovascular diseases (CVD) and low-density lipoprotein cholesterol level (LDL-C) (author’s modification based on [4])
Total CVD risk  
(SCORE) [%]
LDL-C levels
< 70 mg/dL 
< 1.8 mmol/L
70 to < 100 mg/dL 
1.8 to < 2.5 mmol/L
100 to < 155 mg/dL 
2.5 to < 4.0 mmol/L
155 to < 190 mg/dL 
4.0 to < 4.9 mmol/L
≥ 190 mg/dL 
≥ 4.9 mmol/L
< 1 
LDL-C  
< 115 mg/dl
No  
intervention
No  
intervention
No  
intervention
No  
intervention
Lifestyle interven-
tion, consider drug 
if uncontrolled
Class/level I C I C I C I C IIa A
≥ 1 to < 5 
Target: 
LDL-C  
< 115 mg/dl
No  
intervention
No  
intervention
Lifestyle interven-
tion, consider drug 
if uncontrolled
Lifestyle interven-
tion, consider drug 
if uncontrolled
Lifestyle interven-
tion, consider drug 
if uncontrolled
Class/level I C I C IIa A IIa A I A
≥ 5 to < 10 
OR HIGH RISK 
Target: 
LDL-C  
< 100 mg/dl 
< 50–100 mg/dl
No  
intervention
Lifestyle interven-
tion, consider drug 
if uncontrolled
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Class/level IIa A IIa A IIa A I A I A
≥ 10 
OR VERY HIGH RISK 
Target: 
LDL-C  
< 70 mg/dl 
< 35–67.5 mg/dl
Lifestyle in-
tervention, 
consider drug 
if uncontrolled
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Lifestyle interven-
tion and concomi-
tant drug interven-
tion
Class/level IIa A IIa A I A I A I A
SCORE — Systematic COronary Risk Evaluation
diagnosis of metabolic syndrome BPF in people who do not require statin therapy association of BFP with a statin in people not tolerating a higher 
dose of statins or combination therapy with lipid-lowering drugs
MS
MS MS
MS MSMS MS
MS
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in vitro. It seems that BPF modulates the basic pathways 
of cellular signal transduction, which leads to anti-proli-
ferative, anti-ageing and immunomodulatory responses. 
Thanks to their antioxidant and anti-inflammatory proper-
ties, polyphenols may also have a protective effect on the 
myocardium during chemotherapy [10–13].
Potential applications of bergamot 
polyphenols in clinical practice
The possibilities of using BPF go well beyond the metabolic 
syndrome mentioned in the title of this article, including 
a large population of people with low [< 1% SCORE (Sy-
stematic COronary Risk Evaluation)] or moderate (1–4% 
SCORE) cardiovascular risk, with a 20–40% elevation in 
LDL-C when there is no need for aggressive lipid-lowering 
therapy (Table 5). Polyphenols from bergamot may be 
an option in the case of pharmacological intolerance of 
hypolipemic drugs or in patients categorically refusing 
statin therapy, although in this situation, according to the 
clinical condition, every effort should be made to convince 
the patient of the benefits of statin therapy. An important 
feature of bergamot polyphenols, distinguishing them 
from monacolin, is the possibility of statin-associated 
administration in patients who cannot be intensified with 
statin therapy (additive BPF effect). Patients with metabolic 
syndrome and impaired carbohydrate metabolism in the 
form of impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT), and those with metabolic syndrome and 
NAFLD, may benefit significantly from BPF.
Although further research is needed, it is worth remem-
bering that BPF may also be a beneficial complement to 
therapy in erectile dysfunction in patients with carbohydrate 
disorders, and may reduce the effects of UVB radiation, 
as well as being cardioprotective during doxorubicin che-
motherapy.
Summary
The composition of bergamot polyphenols positively 
affects the lipid and carbohydrate metabolism, and their 
strong antioxidant properties additionally have a posi-
tive effect on the vascular endothelium. The effects of 
nutraceutical BPF seem to be comparable to synthetic 
drugs at a low dose, with negligible side effects. BPF 
can be an important supplement, and even occasionally 
an alternative, to conventional drugs as an addition to 
pro-health lifestyle modification and conventional the-
rapy of metabolic syndrome. The features of bergamot 
polyphenols, such as their multidirectional lipid-reduction, 
hypoglycaemic activity, and modification of endothelial 
function, as well as the positive results of clinical trials 
in patients with metabolic syndrome, justify their use in 
this group of patients.
In Figure 1 presents a proprietary application for BFP in 
different populations of people with lipid disorders.
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Streszczenie
Zespół metaboliczny jest uznawany za czynnik ryzyka schorzeń układu sercowo-naczyniowego. Zarówno małe, gęste czą-
steczki lipoprotein o małej gęstości (LDL), jak i dysfunkcja wątroby pod postacią niealkoholowego stłuszczenia wątroby 
(NAFLD) są markerami ryzyka metabolicznego u chorych z zespołem metabolicznym. U pacjentów z zespołem meta-
bolicznym leczonych kompozycją polifenoli z bergamoty stwierdza się obniżenie stężeń glukozy na czczo, triglicerydow 
i cholesterolu frakcji LDL oraz zwiększenia stężenia cholesterolu frakcji lipoprotein o dużej gęstości we krwi. Towarzyszy 
im cofanie się cech NAFLD w badaniu obrazowym, ultrasonograficznym.
Słowa kluczowe: zespół metaboliczny, kompozycja polifenoli z bergamoty
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